OraSure expects Q3 revenue of $29.5M-$32.5M while delaying InteliQuick CT/NG FDA clearance beyond 2026 (NASDAQ:OSUR)
Earnings Call Insights: OraSure Technologies (OSUR) Q2 2026 Management view “Q2 was another important quarter in OraSure's transformation. We exceeded ...
